Alnylam Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US02043Q1076

SecurityALNY / Alnylam Pharmaceuticals, Inc.
InstitutionFirst Horizon Advisors, Inc.
Latest Disclosed Ownership187 shares
Latest Disclosed Value $ 60,978
First Horizon Advisors, Inc. reports 50.81% increase in ownership of ALNY / Alnylam Pharmaceuticals, Inc.

On August 6, 2025 - First Horizon Advisors, Inc. filed a 13F-HR form disclosing ownership of 187 shares of Alnylam Pharmaceuticals, Inc. (US:ALNY) valued at $60,979 USD as of June 30, 2025. The entity filed a previous 13F-HR on April 28, 2025 disclosing 124 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 50.81% during the quarter. The current value of the position is $56,670 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-06 2025-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 187 63 50.81 61 81.82 0.0016
2025-04-28 2025-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 124 0 0.00 33 13.79 0.0009
2025-02-03 2024-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 124 29 30.53 29 11.54 0.0008
2024-11-08 2024-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 95 8 9.20 26 23.81 0.0007
2024-07-19 2024-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 87 -1 -1.14 21 61.54 0.0006
2024-04-26 2024-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 88 0 0.00 13 -18.75 0.0004
2024-02-06 2023-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 88 0 0.00 17 6.67 0.0006
2023-10-27 2023-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 88 -7 -7.37 16 -16.67 0.0006
2023-08-03 2023-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 95 -4 -4.04 18 -5.26 0.0006
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 99 -5 -4.81 20 -20.83 0.0007
2023-02-10 2022-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 104 -7 -6.31 25 14.29 0.0009
2022-11-09 2022-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 111 -19 -14.62 21 16.67 0.0008
2022-08-02 2022-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 130 49 60.49 18 38.46 0.0006
2022-05-10 2022-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 81 12 17.39 13 30.00 0.0005
2022-02-09 2021-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 69 13 23.21 10 0.00 0.0003
2021-11-15 2021-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 56 40 250.00 10 400.00 0.0003
2021-11-09 2021-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 70 54 8 0.0001
2021-08-09 2021-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 16 -7 -30.43 2 -33.33 0.0001
2021-05-11 2021-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 23 0 0.00 3 50.00 0.0002
2021-02-11 2020-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 23 7 43.75 2 0.00 0.0001
2020-11-12 2020-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 16 -66 -80.49 2 -83.33 0.0001
2020-07-31 2020-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 82 -21 -20.39 12 9.09 0.0009
2020-05-05 2020-03-31 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 103 103 11 0.0010
2019-08-05 2019-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 0 -16 -100.00 0 -100.00
2019-04-26 2019-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 16 16 1 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.